The most common lung tumor was Adenocarcinoma followed by small cell carcinoma. Conclusion: As the treatment modalities are different for both of the tumors accurate subtyping of NSCLC into Adenocarcinoma and Squamous cell carcinoma is very essential so that patients get benefit of specific targeted therapy and appropriate molecular testing can be done. FNAC is a very useful and rapid technique for the diagnosis of lung tumor and can be combined with cytochemical and immunohistochemical stains for exact categorization. So that patient can be managed properly and simultaneously tissue can be preserved for molecular studies.
Introduction
Lung carcinoma is one of the most frequent cancer in human beings representing 14% and 13% with mortality rates of 28% and 26% in males and females respectively. [1] . Small biopsies and Fine needle aspiration cytology (FNAC) are the first step diagnostic modalities to diagnose lung cancers and cytologic smears form very important tools to diagnose lung cancers. [2] Lung epithelial tumours are classified into squamous cell carcinoma, adenocarcinoma, small cell carcinoma and large cell carcinoma. [3] However, this classification applies to resected specimens. Previously based on FNAC, the lung carcinomas were classified into Small cell and Non small cell lung carcinomas (NSCLC) due to different management protocols. [2] No further categorization of NSCLC was done which included squamous cell carcinoma, adenocarcinoma and large cell carcinoma and all NSCLCs were treated in a similar way. Recently novel molecular abnormalities involving mutations in Epidermal growth factor receptor gene (EGFR) and translocations involving anaplastic lymphoma kinase (ALK) gene have been identified in adenocarcinomas and specific targeted therapy is available against them. [4, 5] In addition, certain therapies are hazardous in patients with squamous cell carcinomas. [6] Hence accurate subtyping of NSCLC into adenocarcinoma and squamous cell carcinoma is very essential so that patients get benefit of specific targeted therapy and appropriate molecular testing can be done. The distinction between adenocarcinoma and squamous cell carcinoma is now viewed as critical to optimal therapeutic decision making. [2] New guidelines have been published by the International association for the study of lung cancer (IASLC) for reporting of NSCLCs in small biopsies and cytological smears. [7, 8] According to these guidelines, NSCLC should be subtyped into adenocarcinoma and squamous cell carcinoma on morphological features and limited panel of immunohistochemical and mucin stains should be used in doubtful cases. Tissue should also be preserved for molecular studies. Here we describe cytological features of lung tumours on FNAC with special reference to subtyping of NSCLCs on cytologic smears. Remaining 34 cases were diagnosed as primary lung epithelial carcinomas with 6 cases reported as small cell carcinomas(figure4) and 28 cases as NSCLCs. (refer tables 1&2) Non small cell carcinomas were further subtyped into adenocarcinoma(ADC) and squamous cell carcinoma(SCC) based on following features: background, architecture, cytoplasmic and nuclear details and presence of nucleoli. [11, 12] (Table 3) . Based on these features, 12 and 5 cases were subtyped into adenocarcinoma(figure5a,b,c) and squamous cell carcinoma(figure 6)respectively. Nine cases showed overlapping features with large dispersed cells. D-PAS stain was done in these cases. Cytoplasmic positivity was seen in three cases and were finally reported as poorly differentitiated adenocarcinoma(figure 7). Six cases showed negative results and were reported as non small cell carcinoma,not otherwise specified (NSCLC-NOS). Term large cell carcinoma was not used as it should be used in resected specimens only. [9] Two cases showed mixed features (one adenocarcinoma & squamous cell carcinoma, figure8) and other with small cell carcinoma & adenocarcinoma. 
Material & Method

Discussion
Lung carcinoma is one of the most common malignancies in males than in females. Cigarette smoking is the etiological agent in majority of cases and cigarette smokers have a 10 fold increased risk for developing lung cancer than non smokers. Other risk factors include occupational exposures to asbestos and polycyclic aromatic hydrocarbons. [2] Clinically patients present with cough, dyspnea, hemoptysis, chest pain and weight loss.
Lung epithelial tumours are classified into squamous cell carcinoma, adenocarcinoma, small cell carcinoma and large cell carcinoma. [3] This classification is mainly for resected specimens. Adenocarinoma, squamous cell and large cell carcinoma are referred in the broader group as Non small cell carcinoma and comprise about 80-85% of all lung cancers. Small cell and squamous cell carcinomas are most commonly associated with heavy tobacco smoking. [2] Previously based on FNAC and small biopsies, lung tumours were classified into small cell and non small cell types only. No further categorization of NSCLC was done. However, new mutations have been identified in adenocarcinoma including epidermal growth factor receptor gene (EGFR) and translocations involving anaplastic lymphoma kinase (ALK) gene. EGFR mutations include point mutations involving exon 18 to 21. Nearly 90% of lung cancers have point mutations in exon 21 leading to leucine to arginine substitution and inframe Licensed Under Creative Commons Attribution CC BY deletion mutations of exon 19 leading to constitutive activation of protein tyrosine kinase. [4, 5] These EGFR mutations are mostly seen in adenocarcinoma patients (10-35% of NSCLC) and respond to gefitinib and erlotinib. [4, 5] ALK encodes a receptor tyrosine kinase involved in inhibition of apotosis and promotion of cell proliferation through activation of downstream PI3K/Akt and MAPK signaling pathways. The most frequent translocation is EML4-ALK fusion gene product resulting from interstitial deletion and inversion in chromosome 2p. [4, 5] ALK translocations are seen mostly in adenocarcinomas(3-7%) [2] and respond to crizotinib. New molecular testing guidelines have been published jointly by IASLC, College of American Pathologists and Association for Molecular pathology. [10] Hence in view of these recent findings, NSCLC should be subtyped into adenocarcinoma and squamous cell carcinoma. Since majority of patients present in advanced stages, small biopsies and cytologic samples may be the only material available in these patients, accurate subtyping on cytologic materials is very essential. Recent IASLC guidelines provide information regarding reporting of lung cancer on cytological smears. [7, 8] According to these guidelines NSCLCs should be classified into adenocarcinoma and squamous cell carcinoma based on morphological features with minimal panel of IHC markers (Thyroid transcription factor-1, TTF-1 and p63) and mucin stains in doubtful cases. If the doubt persists even after IHC and mucin stains, it should be reported as NSCLS-NOS. Also tissue should be preserved for molecular studies.
Various studies have shown the accuracy of FNAC in subtyping of NSCLC into adenocarcinoma and squamous cell carcinoma. Nizzoli R et al [11] analyzed 474 primary NSCLCs cytologically with comparison of 186 cases with parallel endoscopic biopsies or surgical material and concluded that FNAC is fairly accurate for subtyping of NSCLC and in doubtful cases , immunohistochemistry can be added to improve diagnostic yield. In this study, the authors analyzed adenocarcinoma and squamous cell carcinoma based on background, architecture and cytoplasmic and nuclear characteristics as in the present study. Similarily, Sigel et al found FNAC to be accurate for subtyping of NSCLC. [13] In this study, the authors observed that morphologic evidence of differentitiation as adenocarcinoma or squamous cell carcinoma is more evident in cytologic specimens than small biopsies and found lower need of IHC to type NSCLC than small biopsies. Rekhtman et al [14] also found cytologic specimens suitable for subtyping of NSCLC and also for mutational analysis.
In cases where morphological features fail to subtype NSCLC into adenocarcinoma and squamous cell carcinoma, immunohistochemical markers and mucin stains should be used. Diastase resistant Periodic acid Schiff stain(D-PAS) is used as mucin stain to identify mucin in adenocarinoma. Thyroid transcription factor-1 (TTF-1) and p63 have emerged as the most specific markers for adenocarcinoma and squamous cell carcinoma respectively and various studies have confirmed it [13, 15] . Righi et al [16] used four antibody panel comprising of CK 7, CK 5, TTF-1 and p63 in cell blocks from FNACs of lung tumours (with additional use of p40, naspin A and desmocollin-3 in discordant cases) and found that these four antibody panel helps in subtyping of non small cell carcinoma and reducing the NSCLC-NOS diagnostic category.
In this study, we analyzed 39 lung tumour FNACs and found 34 primary epithelial lung cancers with small cell and non small cell carcinomas comprising 6 (17.6%) and 28 (82.4%) cases respectively. Non small cell carcinomas were further subtyped into adenocarcinoma and squamous cell carcinoma based on conventional light microscopic features and comprised 12 and 5 cases respectively. Three cases were further subtyped into poorly differentitiated adenocarcinoma after D-PAS staining for mucin. Non small cell carcinoma, NOS was diagnosed in 6 cases which were negative for mucin on D-PAS staining. So D-PAS futher helps in subtyping of non small cell carcinoma in doubtful cases. Two cases showed mixed features. Other studies from India have also found adenocarcinoma to be more common on cytology smears and good cytologic and histologic correlation. [17] [18] [19] Hence, we can say that fine needle aspiration cytology is fairly accurate to diagnose lung carcinomas and further subtyping into adenocarcinoma and squamous cell carcinoma with improved sensitivity after application of immunohistochemistry and mucin stains.
In this study, we could not do immunohistochemistry which is the lacunae.
